News & Press
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration with Complete BLA Submission on Track for Fourth Quarter 2022
On August 25, Iovance Biotherapeutics Inc. announced the initiation of a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration for TIL therapy for patients with advanced unresectable or metastatic melanoma. A rolling BLA submission helps expedite the FDA approval process by allowing the company to submit information in pieces for review. Progress towards new treatments for metastatic melanoma brings hope to the entire melanoma community and the MRF is grateful to the countless patients that participate in clinical trials that help lead to future drug approvals. More information is available in the official Iovance press release.